In final guidance, NICE has recommended the use of Biogen Idec’s multiple sclerosis drug, dimethyl fumarate (also called Tecfidera).

The NHS now has a legal obligation to begin funding this treatment for eligible patients within the next 3 months.

Dimethyl fumarate is recommended as a treatment option for adults with relapsing–remitting multiple sclerosis. This is a chronic, disabling, neurological condition that, as it progresses, can be life altering and have a substantial negative impact on quality of life and activities of daily living.

The independent Appraisal Committee, which developed the guidance on behalf of NICE, considered evidence from the manufacturer, clinical experts and patient representatives.

For more details, go to: https://www.nice.org.uk/news/press-and-media/NICE-recommends-new-treatment-option-for-multiple-sclerosis-dimethyl-fumarate